Volitionrx Limited · AMEX:VNRX
Volitionrx — Investor Presentation (November 2015)
20 slides from Volitionrx's investor presentation, Nov 24, 2015
Slide 1: VolitionRx Corporate Presentation
VolitionRx NYSE MKT: VNRX Corporate Presentation » Updated November 2015
Slide 2: Forward-Looking Statements and Disclaimer
Forward-Looking Statements and Disclaimer . This presentation has been prepared by VolitionRx Limited solely for informational purposes. Certain of the information used in this presentation has been obtained from independent industry sources, publications or research reports. This information has be
Slide 3: Seasoned Leadership Team
Seasoned Leadership Team le Cameron Reynolds, MBA President & CEO Background 20+ years entrepreneurial executive expertise; strong experience in management, structuring and strategic planning of start-up companies Previous appointments with Integrated Coffee Technologies, Probio, Inc., Mining House
Slide 4: VolitionRx Overview
VolitionRx Overview VolitionRx is a Clinical Stage, Cancer Diagnostics Company Developing Blood Tests, Beginning With Colorectal Cancer (“CRC”), and Planned Expansion to Pancreatic Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Endometriosis, and Other Diseases Who We Are = Delaware Corp.; R&
Slide 5: Nucleosomics® — Technical Overview
Nucleosomics® — Technical Overview DNA strand Chromosome DNA wrapped around nucleosomes Nucleosomes entering bloodstream @ VOLITION® The DNA in every cell is wound around protein complexes in a “beads on a string” structure Each individual “bead” is called a nucleosome, and consists of DNAwrapped ar
Slide 6: NuQ® VolitionRx's Novel Blood-Based Diagnostic
NuQ® VolitionRx’s Novel Blood-Based Diagnostic NuQ’ Tests Identify and Measure Circulating Nucleosome Structures for the Presence of Epigenetic Cancer Signals Within Blood = The NuQ® family currently consists of 27 NuQ® blood biomarker assays that fall into 5 main families of double antibody ELISA b
Slide 7: Nucleosomes — Diagnostic Potential
Nucleosomes -— Diagnostic Potential Biomarkers Targeted are Unique and Wide Rang id of Detection Very Well Established The VolitionRx Approach = Nucleosomes are a basic structural unit for genes = Elevated cell turnover increases blood nucleosome levels (cancer, heart attack, surgery, severe auto-im
Slide 8: ELISA-Based Platform Makes it Easy & Inexpensive
ELISA-Based Platform Makes it Easy & Inexpensive Cutting-Edge Science that Leverages Robust, Affordable Test Methods Test Advantages SS Ease of use Existing instrumentation already in most labs Established robust methodology allows for low cost per test, and easy to mass produce o 008 Flexible to be
Slide 9: Product Pipeline — Clinical Trials Ongoing
Product Pipeline — 11 Clinical Trials Ongoing Colorectal Cancer Positive 4,800 patient data released 4 ongoing clinical trials Pancreatic Cancer Positive data in two trials recently released Large trials under negotiation Lung Cancer Promising data from one trial released 2 ongoing clinical trials P
Slide 10: Colorectal Cancer — Validation from 4,800-Subject Sample
Colorectal Cancer — Validation from 4,800-Subject Sample NuQ’ Tests Have Demonstrated Significant Accuracy for Colorectal Cancer = 4,800-subject CRC study design — symptomatic population - 4,800 subjects with colorectal cancer, precancerous polyps or adenomas, benign bowel diseases and other maligna
Slide 11: Colorectal Cancer — Comparative Data
Colorectal Cancer — Comparative Data Emerging IV chnologies = EpiGenomics Exact Sciences FOBT (Fecal FIT (Fecal (Epi proColon) DNACologuard Colonoscopy Occult) Immunochemical) CRC Sensitivity 68% 22% 95% 13% 66% Pre— Cancer Polyp 20% 2% 95% 11% 22% Sensitivity Specificity 78% 87% 90% 95% 95% Price (
Slide 12: Additional CRC Clinical Trials
Additional CRC Clinical Trials Number of ject: Study Details Data Expected Symptomatic subjects with colorectal cancer, polyps or adenomas, Ongoing analysis of the Colorectal Cancer come 4,800 benign bowel diseases, or other malignancies NuQ® biomarkers against this (symptomatic population) pena rk)
Slide 13: The Market for Colorectal Cancer Tests
The Market for Colorectal Cancer Tests European Cancer Statistics 432 000 "We believe that the European Union (EU) is a large opportunity 3 with faster time to market due to CE Mark process EU has relatively higher compliance for fecal screening offering potential for rapid market adoption of a simp
Slide 14: Pancreatic Cancer — Pilot Study Lund University
Pancreatic Cancer — Pilot Study Lund University Discrimination for 4 NuQ” assay panel combined 5 NuQ® Panel — with CA19-9 = 84% sensitivity, 90% specificity — Cancer vs. healthy 2 = 72% sensitivity, 90% specificity 1 — Cancer vs. healthy and benign 04 e m—_ 4NuC@PPanel+ CA19-9 ———_ | . = 92% sensiti
Slide 15: The Market for Pancreatic Cancer Tests
The Market for Pancreatic Cancer Tests Relevant Cancer Statistics 338,000 New pancreatic caner cases globally p/a’ 46 million tests CA19-9 testing market for PC by 2019? (US, UK, France, Germany, Italy, Spain, Japan) 3. 4, 5. European and US Opportunity for Pancreatic Cancer Tests = Lifetime risk 1.
Slide 16: The Estimated Market for Pancreatic Blood Test Targeting High Risk Groups
The Estimated Market for Pancreatic Blood Test Targeting High Risk Groups Risk Factor Percentage Increase Risk At Risk Population Estimate Familial (3 1% gen) 3200%! e é (2 1% gen) 600-700% 33,800 families per year (Global) (1.1% gen) 400-500% Hereditary _ : (BRCA2, PALB2, ATM) 1000%? 1.8 million (E
Slide 17: Lung Cancer — Pilot Study CHU
Lung Cancer — Pilot Study CHU Beyond Significant Accuracy for Colorectal Cancer, NuQ * Tests Have Also Demonstrated Broad Applications in the Detection of Other Cancers Such as Lung Cancer * Pilot study evaluating NuQ® performance detecting lung cancer at Centre Hospitalier Universitaire (CHU) de Li
Slide 18: Other Clinical Trials
Other Clinical Trials Number of ject Study Details Data Expected Study to evaluate Nua® for early detection of 27 most prevalent cancers; and to evaluate differences in nucleosome structures 27 Most Bonn between cancers University Subjects with cancers including respiratory cancer, gastrointestinal
Slide 19: Numerous Milestones Upcoming
Numerous Milestones Upcoming Clinical Milestones Data from MD Anderson Cancer Center study in prostate cancer Lung cancer — launch pilot - Belgium Training set developed from 2,500 patients in 14,000 subject prospective Danish CRC trial Data from 800 patient Danish adenoma trial Possible additional
Slide 20: VolitionRx
VolitionRx NYSE MKT: VNRX Cameron Reynolds, President and CEO c.reynolds@volitionrx.com Scott Powell, Vice President, Investor Relations s.powell@volitionrx.com +1 (646) 650 1351 » VolitionRx Belgian Volition SA Centre Technologique 20A Rue du Séminaire BE-5000 Namur Belgium www. volitionrx.com